ABSTRACT Introduction Medication errors have been associated with poor patient outcomes and pose significant public health consequences. Establishing medication safety quality indicators is crucial to capturing the pervasiveness of preventable errors and is a fundamental first step in the process of improvement. In this article, a study is presented in which a set of medication prescribing and monitoring quality indicators were developed, and adherence to them was assessed among a group of US primary care practices. Methods Twenty Practice Partner Research Network practices in 14 US states with 94 clinicians and 52 246 active adult patients participated in the study. All practices use a common electronic medical record with dosing, interaction and monitoring decision support features. A consensus development process was used to select indicators in the categories of inappropriate treatment, dosing, drugedrug and drugedisease interactions, and monitoring of potential adverse events. Data extracted electronically from practices' electronic medical record were used to assess practice-level adherence with the indicator set as of 1 July 2008. Results Thirty medication safety indicators were selected. Across all practices, inappropriate treatment, dosing, drugedrug and drugedisease interactions were avoided in 75%, 84%, 98% and 86% of eligible patients, respectively; monitoring of preventable adverse drug events occurred in 75% of patients. There was wide variability in practice adherence with the indicators. Discussion The consensus development process was successful in selecting a broad set of primary care medication safety quality indicators. Although aggregate adherence was relatively high in this group of practices, opportunities exist to improve potential errors in treatment selection, dosing and monitoring.
Medication errors have significant public health consequences. Nearly 10 years ago, medication safety garnered significant attention in the USA when the Institute of Medicine called for a focused patient safety effort. 1 2 Since then, the majority of improvement efforts have been in the hospital setting, where medications can be tracked and adverse events are apparent. In the ambulatory arena, nearly four billion prescriptions are purchased annually, and the majority of US adults take at least one medication. 3 4 Despite this ubiquitous use, surprisingly little is known about the incidence of preventable medication errors in the outpatient primary care setting. Furthermore, methods to assess medication safety are limited, and comprehensive quality indicators are lacking.
The medication use process involves multiple steps, including prescribing, procuring the drug, dispensing, patient adherence and monitoring the patient's response. Errors can occur during any step of the process, making the assessment of medication safety a complex endeavour. Although no standardised taxonomy exists, an adverse drug event (ADE) is generally considered to be any injury due to medication. 5 More broadly, a medication error is considered to be any error occurring in the medication-use process, regardless of whether injury occurs. 6 This term encompasses a much more sizeable catalogue of medication-related problems and preventable ADEs, including untreated indications, improper dosing, inappropriate medication use, failing to avoid drugedrug or drugedisease state interactions, failing to monitor a drug's effects and patient nonadherence. 7 Only a fraction of medication errors result in actual ADEs, yet the avoidance of these errors is essential for optimal patient safety. 5 The majority of studies regarding outpatient medication safety discuss ADEs and preventable ADEs, the latter of which are most often associated with errors in the prescribing or monitoring phases.
8e12 Fewer studies address the broader concept of "medication errors", typically rely on survey or administrative data and are subject to bias or incompleteness.
13e15 Another limitation to assessing medication safety is the limited number of relevant indicators, most of which focus on pharmacologic care of the elderly. 16e18 This study addresses the limitations of the current literature by using a consensus development process to select a broad set of primary care prescribing and monitoring indicators and by assessing adherence to them using electronic medical record data.
METHODS
The study was conducted in the Practice Partner Research Network (PPRNet), a primary care practice-based research network among users of a common electronic medical record (EMR) ( The medication safety indicator consensus development process occurred in five phases. Similar to other published methods, 19 the phases included preselection, adding and rating, potential indicator review, reflection and combination of similar measures. PPRNet members and participating clinicians served as the expert panel in this process. First, 90 potential medication prescribing and monitoring indicators were identified, drawn from published medication-related quality indicators 18 20e24 and the functionality embedded in the decision support features of PP. Next, a session was conducted at the 2007 PPRNet network meeting in which 12 primary care physicians provided iterative feedback to the research team on the content of the indicator set and a recommended number of indicators for inclusion in practice reports. Based on an available taxonomy, 7 indicators were grouped into five categories: potentially inappropriate treatment, inappropriate dosing, drugedrug interactions, drugedisease interactions and monitoring or prevention of ADEs. Third, the lead clinician from each participating practice then completed a survey to prioritise 40 of the 90 proposed indicators. Fourth, indicators with greater than the median number of votes for inclusion (median 9.5, n¼52 indicators) were reviewed by the research team for primary care relevance and feasibility of programming from available EMR data. Clinicians from four practices also provided feedback on pilot practice performance reports. Eight indicators were excluded during this step because of limited relevance (eg, monitoring of thyroid-stimulating hormone in patients on lithium) or programming feasibility (eg, change in serum creatinine of less 30% after ACE inhibitor initiation), resulting in a final set of 44 indicators. Finally, groups of similar measures, such as nonsteroidal anti-inflammatory drugedisease interactions and serum creatinine monitoring, were combined, which further streamlined the set to 30 indicators. Each indicator was supported by at least one of the decision support features.
Data electronically extracted from the EMRs of participating practices were used to assess practice-level adherence by category and for each specific indicator as of 1 July 2008. Active patients were defined as those with a progress note in the prior 12 months who were not subsequently identified as deceased, transferred or inactive. Prescriptions were considered active if they were written in the last year and lacked a discontinuation date. A discontinuation date was calculated for prescriptions with a documented duration. Active problems were obtained from documentation on a problem list or as a diagnosis code within the last 3 years. For renal dosing indicators, creatinine clearance was estimated using the CockcrofteGault equation based on the most recent serum creatinine and actual body weight. 25 Ideal body weight was not calculated due to the absence of consistent recording of height data in the EMR. Practice adherence was calculated as the number of eligible patients who met the indicator criterion divided by the total number of eligible patients as defined in table 2. Median and benchmark adherence across the 20 participating practices were then calculated for each indicator. The PPRNet benchmark uses the Achievable Benchmark of Care algorithm, which assures that high-performing practices with few eligible patients do not overly influence the final benchmark. 40 41 For each of the indicator categories, summary adherence was calculated as the percentage of patients meeting criteria for every indicator for which they were eligible out of the total number of patients eligible for any indicator within that category. Thus, if patients were eligible for more than one indicator in a given category, they had to meet criteria for each indicator to be classified as adherent.
RESULTS
As of 1 July 2008, there were 52 246 active patients over 18 years of age in the 20 participating practices and 31 379 patients (60.1%) were eligible for at least one medication safety indicator. Table 2 describes the PPRNet Medication Safety final indicator set, total number of eligible patients by indicator, the practice adherence range, median and benchmark. The number of practices meeting the benchmark is also presented. Practice adherence was highly variable for indicators across categories, with the exception of avoiding potential drugedrug interactions in which medians ranged from 95% to 100%. High medians were also observed for the drugedisease interaction category. The lowest median practice adherence occurred for dosing, treatment selection and monitoring categories. Across all indicators, there were 120 626 opportunities for potential errors to occur, of which errors were avoided 88% of the time.
Summary adherence by medication safety category is presented in table 3. Overall, the highest adherence was observed for the category of avoiding drugedrug interactions, with potential drugedrug interactions being avoided in 98% of eligible patients. The lowest adherence rates were for avoidance of inappropriate treatment and appropriate monitoring of potential ADEs, which both occurred in 75% of eligible patients. Avoiding potential drugedisease interactions Avoidance of anticholinergics in dementia 18 29 Pts with dx of dementia (n¼429) 86 (0e100) 
DISCUSSION
In this study, we developed a broad set of prescribing and monitoring quality indicators for use in primary care practice. The selected indicators reflect five key aspects of medication safety, and adherence was assessed from the EMR data of 20 primary care practices. High adherence with indicators such as avoiding inappropriate medications in the elderly, drugedrug interactions and some drugedisease interactions may be attributed to embedded EMR alerts that require a response from clinicians before completing a prescription. Lower adherence with renal dosing and monitoring indicators may be due to the need for further action by the clinician, such as invoking additional clinical decision support or ordering laboratory tests. Our ability to compare these findings with others is limited due to the relatively sparse existing literature. However, our findings are similar to others for medication monitoring and medication use in the elderly and somewhat better for the specific indicator of anticholinergic medications in patients with dementia. 18 This study has several limitations. First, despite the breadth of the selected indicators, this set does not represent the full spectrum of medication safety. Categories such as therapeutic duplications, untreated indications, medications without an indication and medication use in pregnancy are not included. 7 These categories were excluded before indicator development due to lack of defined indicators or decision support tools, or during the development process due to low clinician interest. A formal round of reliability testing, as suggested by some researchers, 19 was not applied to the consensus development process for this set of indicators based on the level of agreement from participating clinicians during the rating stage. Calculated adherence to study indicators may be biased if EMR medication lists were incomplete, 42 if problem lists or diagnosis codes were inaccurate or if laboratory data were not recorded in the EMR. The exclusion of deceased patients may have led to an underestimation of errors. Additionally, variability in EMR use across the sample of practices may have influenced the use of decision support features as well as adherence. Findings from this study may not be generalisable to practices without medicationspecific decision support tools or those who do not participate in quality improvement projects.
Despite these limitations, this is, to our knowledge, the first evaluation of multiple categories of medication errors in a geographically diverse group of independent US primary care practices. Since clinicians contributed to their development, these indicators are more likely to be accepted by them. Although EMR data may be incomplete, the calculation of prescribing and monitoring error rates from clinical EMR data overcome the inherent limitations of surveys or administrative data sets. This study provides a replicable set of medication safety indicators and specificity to the scope of prescribing and monitoring improvement needed in primary care practices. Annual haemoglobin and platelet count 1 35 Pts with active rx for anti-platelet (excluding aspirin) or oral anticoagulant (n¼1962)
Annual glucose 36 37 Pts with active rx for antipsychotic (n¼733)
Annual weight 36 37 Pts with active rx for antipsychotic (n¼733) xOne practice had no eligible patients. {Annual for all classes listed except in the past 6 months for high-risk patients $65 years of age or CrCl <50 ml/min on (ACEI or ARB) and K-sparing combination.
**Thiazide, loop, K-sparing or spironolactone. We view our current study as an initial step in the process of exploring safe prescribing and monitoring in primary care practice. Our preliminary findings are that primary care practices with EMRs have relatively high adherence with a broad set of medication safety indicators but that opportunities exist to improve in the areas of inappropriate treatment, dosing and monitoring. Additional studies should involve larger numbers of practices, assess the relationship between use of specific decision support tools and medication errors, examine the characteristics of practices that achieve high adherence with medication safety indicators and test interventions designed to improve adherence with them.
CONCLUSION
Due to the expansive array of potential medication errors, developing strategies to identify such errors is a daunting task; however, it is also a crucial step in the pathway to improving medication safety. Furthermore, identifying errors requires the development of a comprehensive set of medication safety indicators. To our knowledge, this project demonstrates the first application of a broad set of prescribing and monitoring quality indicators to a group of primary care practices in the USA. Overall, 88% of potential medication errors as defined by 30 selected indicators were avoided in participating PPRNet practices. Ample opportunities exist to improve medication safety at the primary care practice level, specifically in the areas of treatment selection, dosing and monitoring.
